Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REQUITE

Financiado

Cerrado

Validating predictive models of radiotherapy toxicity to improve quality of life...

Validating predictive models of radiotherapy toxicity to improve quality of life and reduce side effects in cancer survivors Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predicted in advance. Previous work identified clinical and biological predictors but a major,... ver más

30/09/2018

UNIVERSITY OF MANC...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

THE UNIVERSITY OF MANCHESTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 16 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-09-30 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

UNIVERSITY OF MANCHESTER

0.00€ | Lider

ICM-VAL D'AURELLE

N.D. | Participante

KU Leuven

N.D. | Participante

ICAHN SCHOOL OF MEDICINE AT...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PRO-ORATICA PRedictive mOdeling Of RAdiaTion Induced CArdiotoxicity afte... 161K€ Cerrado

NovaTests The first predictive test for radio sensitivity. A step towa... 71K€ Cerrado

BOUNCE Predicting Effective Adaptation to Breast Cancer to Help Wom... 5M€ Cerrado

EU-TOPIA EU TOPIA TOWARDS IMPROVED SCREENING FOR BREAST CERVICAL AN... 3M€ Cerrado

SAF2016-75197-R DESARROLLO DE UN MODELO PREDICTIVO DE LA FALTA DE RESPUESTA... 97K€ Cerrado

PDC2022-133520-I00 VALIDACION Y TRASFERENCIA DE DATOS Y BIOMARCADORES ONCOLOGIC... 127K€ Cerrado

Líder del proyecto

THE UNIVERSITY OF MANCHESTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predicted in advance. Previous work identified clinical and biological predictors but a major, coordinated approach is needed to validate them so they can be used clinically. The EU has ~17.8 million people living with a prior diagnosis of cancer of whom ~7 million received radiotherapy. In the long-term, potentially 20% of those suffering with mild to severe side-effects (~1.4 million) might benefit from alleviation of symptoms, with resulting reductions in the cost of care in the EU. REQUITE aims to develop validated clinical models and incorporate biomarkers to identify before treatment cancer patients at risk of side-effects and use the models to design interventional trials aimed at reducing side-effects and improving QoL in cancer survivors who underwent radiotherapy. REQUITE will: 1. carry out a multi-centre, longitudinal, observational study to collect standardised data and samples in breast, prostate and lung cancer patients; 2. validate biomarkers with published evidence of predictive value; 3. replicate published clinical models and incorporate replicated biomarkers to create validated predictive algorithms; 4. use the prospectively validated models and biomarkers to design interventional trial protocols aiming to reduce side-effects and improve QoL in high-risk patients. REQUITE builds on collaborations with a proven history of data sharing, enlarged to a consortium with expertise in patient recruitment, knowledge management, biomarker testing and predictive model development. SME involvement for biomarker assays will facilitate future clinical implementation and commercial exploitation. The outcome of this project will be validated predictive models for three common cancers and trial protocols using the models to investigate interventions aimed at reducing long-term side-effects and improving the QoL of cancer survivors.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores